NHS England today published its updated procedure for evaluating drugs in the Cancer Drugs Fund (CDF), which will mean more effective and promising drugs will be prioritised and made available to patients.

Since it was established in 2010, more than 55,000 patients have accessed treatment through the CDF – around 2,000 every month.

Last week NHS England’s board confirmed its support for proposed changes to the evaluation process for drugs available via the CDF, after considering responses to a four-week consultation on plans set out earlier this year.

For more information view the feedback received during consultation and read the revised Standard Operating Procedure.